Microbiome Therapeutics Market Size, Share & Analysis Report, 2024-2033
The global microbiome therapeutics market size was exhibited at USD 94.88 billion in 2023 and is projected to hit around USD 1,956.30 billion by 2033, growing at a CAGR of 35.34% during the forecast period 2024 to 2033.
Key Takeaways:
Microbiome Therapeutics Market Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 128.41 Billion |
| Market Size by 2033 | USD 1,956.30 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 35.34% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Type, Application, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | OpenBiome; Seres Therapeutics Inc.; 4D Pharma plc.; Locus Biosciences, Inc.; Enterome SA; Finch Therapeutics Group, Inc.; Intralytix, Inc.; Microbiotica; Second Genome; Rebiotix Inc.; Vedanta Bioscience, Inc. |
The market is witnessing growth due to the factors such as the increasing number of strategic collaborations for microbiome therapeutics for R&D, product development, the projected launch of novel drugs, and portfolio enhancement. For instance, in January 2023, Hudson Institute and BiomeBank entered into a 4-year collaboration for the development and discovery of microbial therapies. Furthermore, a significant increase in the prevalence of target diseases is boosting the demand for microbiome therapeutics.
The COVID-19 pandemic had a significant negative impact on the market for microbiome therapeutics. Clinical trial research was severely disrupted globally. This is especially true considering that trials frequently include weaker populations who are most at risk of being exposed to COVID-19. The COVID-19 pandemic and the suspension of non-essential medical procedures, such as endoscopies, at numerous clinical sites had a negative effect on Seres Therapeutics' SER-287 development activity.
The majority of therapeutic agents in the pipeline are in the early stages of development, roughly in Phase I and Phase II. For GI indications, over 13 drugs are being investigated out of 23, with the majority targeting ulcerative colitis. For instance, in 2021, Seres Therapeutics, Inc. announced data of SER-109, released from its Phase 3 ECOSPOR III study. The pipeline drug is under investigation as an oral therapy for recurring C. difficile infection with an anticipated launch in the first half of 2023. In contrast to placebo, SER-109 is linked to a decline in antimicrobial resistance genes.
The advancements in microbiome research are expected to aid the discovery of better treatments for infections and other diseases, which will enhance the outcomes of medical care. To aid the adoption of microbiome-based treatments, companies are lowering the cost of their products and making cutting-edge medical care more accessible to a larger portion of the population, and a few nations governing bodies are restructuring their approaches. Resultantly, this provides market vendors with profitable growth prospects to improve their market share.
Stringent regulatory guidelines owing to the complex nature of the product and the high cost of microbiome therapeutics are major factors restraining the growth of the market. High cost of development, production, and stringent & lengthy regulation processes increase the overall cost of the product and, thereby, impact the treatment cost. For instance, the out-of-pocket cost of screening one’s donor can exceed USD 3500, while FMT capsules are available at USD 2050 per dose.
Segments Insights:
Type Insights
Fecal microbiota therapy (FMT) dominated the microbiome therapeutics market in 2023 with a share of 94.0%. The dominance of the segment is attributed to its wide usage in the treatment of C. difficile infection. Moreover, increasing R&D focusing on developments to discover other therapeutic applications of FMT and the introduction of capsules in the market is expected to drive the growth. For instance, in February 2021, new direct testing for SARS-COV-2 was announced by OpenBiome in fecal microbiota therapy preparation which is aimed at increasing the availability of FMT to any scheduled patient for emergency use without infection transmission risk.
Microbiome drugs are expected to expand at the fastest rate of 49.1% over the forecast period attributable to the presence of a robust pipeline and the development of advanced and novel drugs. The majority of drugs are still in the developmental stages. For instance, 4D Pharma plc’s drug, Blautix is under Phase II stage of clinical trials which is a single strain biotherapeutic product, under investigation for the treatment of both IBS-C and IBS-D.
Application Insights
Clostridium difficileinfection (CDI or C. difficile) application segment is projected to expand at the fastest growth rate with a CAGR of 37.34% from 2024 to 2033. The growth of this segment is attributed to the increasing use of Fecal microbiota transplants (FMT) in the treatment of C. difficile. According to a study published in 2020, by the University of Birmingham, FMT is highly accepted for the treatment of patients suffering from Clostridium difficile infections. Further, FMT is more efficient in the treatment of C difficile than an antibiotic, especially in recurrent cases.
Crohn’s disease application segment is expected to show lucrative growth during the forecast period owing to enhanced focus on gut microbial changes in patients with the condition. For instance, as per the Microbiome Journal in 2020, remission of Crohn’s disease can be maintained in patients with the use of fecal microbiota transplantation.
Regional Insights
North America dominated the market with the largest market share of 76.0% in 2023. Highly established research facilities for the development of novel therapeutics and increasing target population are the major factors for the dominance of the region. Further, the prevalence of programs such as the Canadian Microbiome Initiative (CMI) in Canada facilitates collaboration with stakeholders and partners. This allows the focusing of research efforts on microbiome therapeutics development. For instance, in July 2021, Biocodex Microbiota Foundation announced a call for proposals for microbiome studies in Canada for over USD 26,000 in research grants. These grants are expected to fuel new developments in the market.
Europe is estimated to demonstrate significant growth of 35.4% during the forecast period. Germany is an emerging market in Europe for microbiome therapeutics. Despite the high cost of microbiome therapeutics, supportive reimbursement policies are expected to facilitate treatment adoption in upcoming years. Furthermore, startups are receiving funding to research and introduce microbiome-based products.
Some of the prominent players in the Microbiome therapeutics market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global microbiome therapeutics market.
Type
Application
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers